Introduction: The standard induction chemotherapy in newly diagnosed acute myeloid leukemia (AML) is 7 days cytarabine and 3 days daunorubicin. However, older and frail patients cannot be treated intensively. Before hypomethylating agents (HMA) plus venetoclax (VEN) was established we formulated a more tolerable induction therapy for these patients using continuous infusions of reduced doses of cytarabine (A) and idarubicin (IDA) in combination with ATRA (A), the (A)-AIDA regimen and trying to reach noteworthy and relevant remission rates with acceptable toxicities in this special population. Methods: Between 1998 and 2015 older/frail patients with newly diagnosed or relapsed AML received (A)-AIDA. Treatment consisted of cytarabine 100 mg/m2/d d1–5 and IDA 5 mg/m2/d d1–5 as continuous infusion. Since 2003 ATRA (45 mg/m2/d d4–6, 15 mg/m2/d d7–28) was added in some patients. Results: 154 patients received (A)-AIDA, median age was 71 years. In 40% the AML was secondary, 15.6% had relapsed AML. The complete remission rate was 41%, 7% reached a partial remission, the median overall survival was 7 months. No significant differences of remission rates regarding various known risk factors for outcome with (A)-AIDA were detected. Conlusion: Recent studies established HMA/VEN as first-line treatment for older/frail AML patients. Because (A)-AIDA is equally effective in patients with secondary or relapsed AML or ECOG >1, this regimen is an interesting treatment option for patients uneligible to HMA/VEN regimens.

1.
Oran
B
,
Weisdorf
DJ
.
Survival for older patients with acute myeloid leukemia: a population- based study
.
Haematologica
.
2012
;
97
(
12
):
1916
24
.
2.
DiNardo
CD
,
Jonas
BA
,
Pullarkat
V
,
Thirman
MJ
,
Garcia
JS
,
Wei
AH
, et al
.
Azacitidine and venetoclax in previously untreated acute myeloid leukemia
.
N Engl J Med
.
2020
;
383
(
7
):
617
29
.
3.
Döhner
H
,
Weisdorf
DJ
,
Bloomfield
CD
.
Acute myeloid leukemia
.
N Engl J Med
.
2015
;
373
(
12
):
1136
52
.
4.
Schlenk
RF
,
Fröhling
S
,
Hartmann
F
,
Fischer
JT
,
Glasmacher
A
,
del Valle
F
, et al
.
Phase III study of all-trans retinoic acid in previously untreated patients 61 years or older with acute myeloid leukemia
.
Leukemia
.
2004
;
18
(
11
):
1798
803
.
5.
Löwenberg
B
,
Ossenkoppele
GJ
,
van Putten
W
,
Schouten
HC
,
Graux
C
,
Ferrant
A
, et al
.
High-dose daunorubicin in older patients with acute myeloid leukemia
.
N Engl J Med
.
2009
;
361
(
13
):
1235
48
.
6.
Wiernik
PH
,
Banks
PL
,
Case
DJ
,
Arlin
ZA
,
Periman
PO
,
Todd
MB
, et al
.
Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia
.
Blood
.
1992
;
79
(
2
):
313
9
.
7.
Robert
J
,
Rigal-Huguet
F
,
Harousseau
JL
,
Pris
J
,
Huet
S
,
Reiffers
J
, et al
.
Pharmacokinetics of idarubicin after daily intravenous administration in leukemic patients
.
Leuk Res
.
1987
;
11
(
11
):
961
4
.
8.
Leoni
F
,
Ciolli
S
,
Giuliani
G
,
Pascarella
A
,
Caporale
R
,
Salti
F
, et al
.
Attenuated-dose idarubicin in acute myeloid leukaemia of the elderly: pharmacokinetic study and clinical results
.
Br J Haematol
.
1995
;
90
(
1
):
169
74
.
9.
Schlenk
RF
,
Döhner
K
,
Kneba
M
,
Götze
K
,
Hartmann
F
,
Del Valle
F
, et al
.
Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B
.
Haematologica
.
2009
;
94
(
1
):
54
60
.
10.
von Lilienfeld-Toal
M
,
Hahn-Ast
C
,
Kirchner
H
,
Flieger
D
,
Dölken
G
,
Glasmacher
A
.
A randomized comparison of immediate versus delayed application of G-CSF in induction therapy for patients with acute myeloid leukemia unfit for intensive chemotherapy
.
Haematologica
.
2007
;
92
(
12
):
1719
20
.
11.
Cheson
BD
,
Bennett
JM
,
Kopecky
KJ
,
Büchner
T
,
Willman
CL
,
Estey
EH
, et al
.
Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia
.
J Clin Oncol
.
2003
;
21
(
24
):
4642
9
.
12.
Döhner
H
,
Estey
E
,
Grimwade
D
,
Amadori
S
,
Appelbaum
FR
,
Büchner
T
, et al
.
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
.
Blood
.
2017
;
129
(
4
):
424
47
.
13.
Glasmacher
A
,
Prentice
AG
.
Evidence-based review of antifungal prophylaxis in neutropenic patients with haematological malignancies
.
J Antimicrob Chemother
.
2005
;
56
(
Suppl 1
):
i23
32
.
14.
Burnett
AK
,
Milligan
D
,
Prentice
AG
,
Goldstone
AH
,
McMullin
MF
,
Hills
RK
, et al
.
A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment
.
Cancer
.
2007
;
109
(
6
):
1114
24
.
15.
Kantarjian
HM
,
Thomas
XG
,
Dmoszynska
A
,
Wierzbowska
A
,
Mazur
G
,
Mayer
J
, et al
.
Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia
.
J Clin Oncol
.
2012
;
30
(
21
):
2670
7
.
16.
Dombret
H
,
Seymour
JF
,
Butrym
A
,
Wierzbowska
A
,
Selleslag
D
,
Jang
JH
, et al
.
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with 30% blasts
.
Blood
.
2015
;
126
(
3
):
291
9
.
17.
DiNardo
CD
,
Maiti
A
,
Rausch
CR
,
Pemmaraju
N
,
Naqvi
K
,
Daver
NG
, et al
.
10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial
.
Lancet Haematol
.
2020
;
7
(
10
):
e724
36
.
18.
Montesinos
P
,
Recher
C
,
Vives
S
,
Zarzycka
E
,
Wang
J
,
Bertani
G
, et al
.
Ivosidenib and azacitidine in IDH1-mutated acute myeloid leukemia
.
N Engl J Med
.
2022
;
386
(
16
):
1519
31
.
19.
Bewersdorf
JP
,
Zeidan
AM
.
Hyperleukocytosis and leukostasis in acute myeloid leukemia: can a better understanding of the underlying molecular pathophysiology lead to novel treatments
.
Cells
.
2020
;
9
(
10
):
2310
.
20.
Appelbaum
FR
,
Gundacker
H
,
Head
DR
,
Slovak
ML
,
Willman
CL
,
Godwin
JE
, et al
.
Age and acute myeloid leukemia
.
Blood
.
2006
;
107
(
9
):
3481
5
.
21.
Kantarjian
H
,
Ravandi
F
,
O’Brien
S
,
Cortes
J
,
Faderl
S
,
Garcia-Manero
G
, et al
.
Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia
.
Blood
.
2010
;
116
(
22
):
4422
9
.
22.
Granfeldt Østgård
LS
,
Medeiros
BC
,
Sengeløv
H
,
Nørgaard
M
,
Andersen
MK
,
Dufva
IH
, et al
.
Epidemiology and clinical significance of secondary and therapy-related acute myeloid leukemia: a national population-based cohort study
.
J Clin Oncol
.
2015
;
33
(
31
):
3641
9
.
23.
Lalayanni
C
,
Gavriilaki
E
,
Athanasiadou
A
,
Iskas
M
,
Papathanasiou
M
,
Marvaki
A
, et al
.
Secondary acute myeloid leukemia (sAML): similarly dismal outcomes of AML after an antecedent hematologic disorder and therapy related AML
.
Clin Lymphoma Myeloma Leuk
.
2022
;
22
(
4
):
e233
40
.
24.
Kurosawa
S
,
Yamaguchi
T
,
Miyawaki
S
,
Uchida
N
,
Sakura
T
,
Kanamori
H
, et al
.
Prognostic factors and outcomes of adult patients with acute myeloid leukemia after first relapse
.
Haematologica
.
2010
;
95
(
11
):
1857
64
.
25.
Döhner
H
,
Wei
AH
,
Appelbaum
FR
,
Craddock
C
,
DiNardo
CD
,
Dombret
H
, et al
.
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
.
Blood
.
2022
;
140
(
12
):
1345
77
.
26.
Abbas
S
,
Lugthart
S
,
Kavelaars
FG
,
Schelen
A
,
Koenders
JE
,
Zeilemaker
A
, et al
.
Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value
.
Blood
.
2010
;
116
(
12
):
2122
6
.
You do not currently have access to this content.